Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
- 1 November 2015
- journal article
- research article
- Published by Elsevier in The Lancet HIV
- Vol. 2 (11) , e464-e473
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort studyJournal of Bone and Mineral Research, 2013
- Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyJournal of Bone and Mineral Research, 2013
- Fractures after antiretroviral initiationAIDS, 2012
- Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-LamivudinePLOS ONE, 2012
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsAIDS, 2012
- Higher Rates of Bone Loss in Postmenopausal HIV-Infected Women: A Longitudinal StudyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202The Journal of Infectious Diseases, 2011
- Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care ProvidersClinical Infectious Diseases, 2010
- Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare SystemThe Journal of Clinical Endocrinology & Metabolism, 2008
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factorsAIDS, 2008